SAN DIEGO, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, announced today the pricing of its initial public offering of 5,500,000 shares of its common stock at $8.00 per share. Celladon has also granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock to cover overallotments, if any. All shares of the common stock in the offering are being sold by Celladon. Celladon’s common stock is scheduled to begin trading on The NASDAQ Global Market on January 30, 2014 under the symbol “CLDN.” The offering is scheduled to close on February 4, 2014, subject to customary closing conditions.
Help employers find you! Check out all the jobs and post your resume.
